Evidence map›GLP-1 receptor agonists × glycemic control›PMID 31984646›Full record

Trial reportDiabetes, obesity & metabolism2020

Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.

Lawrence Blonde, Lidia Belousova, Udi Fainberg, Pedro A Garcia-Hernandez, Sunil M Jain, Margit S Kaltoft, Ofri Mosenzon, Jalal Nafach, Mads Sundby Palle, Rosangela Rea

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2020. The graph read 1 number from its abstract, feeding 1 cell of the map: it supports the treatment in 1. It reports registered trial NCT02964247. Cited by 26 papers, 5 of them syntheses that pooled it.

1number the graph read from it
1cell of the map it votes in
26citing papers in PubMed, 5 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

← favours the treatmentfavours the comparator →
-0.890 · no effect
Glycemic controlfavours the treatment · against placebo · t2dfeeds one cell of the map
Δ -0.68-0.89 to -0.48P < 0.001
Mean changes in HbA1c from baseline to week 26 with liraglutide (n = 202) and placebo (n = 100) were - 0.98% and - 0.30%, respectively (estimated treatment difference [ETD]: -0.68% [95% CI: -0.89, -0.48]; P < 0.001).
FeedsGLP-1 receptor agonists×glycemic control

clause the extractor read what became the number

2 · Its place on the map

Where it lands on the map

Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.

supports the treatmentfavours the comparatorno clear differenceread, but no usable result
3 · What it changes

What it adds to each cell

For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.

GLP-1 receptor agonists×glycemic control

SupportsOpen on the map →What to test next →

40 readable studies in this cell: 96 favour the treatment, 17 find no difference, 10 favour the comparator.

Belief with this paper
0.91replicated · 68 families support, 7 contradict · against placebo
Without it
0.91This paper does not move the number.
← favours the treatmentfavours the comparator →
0 · no effect
This paper’s trial, registry resultNCT02964247 · 303 enrolled · 2017
Δ -0.68-0.89 to -0.48
This paper · 2020
Δ -0.68-0.89 to -0.48
NCT017204463,297 enrolled · 2013
Δ -0.66-0.80 to -0.52
NCT036893742,274 enrolled · 2018
Δ -0.29-0.38 to -0.20
NCT039879191,879 enrolled · 2019
Δ -0.51-0.64 to -0.38
NCT026078651,864 enrolled · 2016
Δ -0.50-0.60 to -0.40
NCT013360231,663 enrolled · 2011
Treatment contrast -0.64-0.75 to -0.53
NCT040178321,441 enrolled · 2019
Δ -0.20-0.30 to -0.10
NCT018365231,398 enrolled · 2013
Δ -0.20-0.32 to -0.07
NCT019301881,231 enrolled · 2013
Δ -1.06-1.21 to -0.91
NCT007344741,202 enrolled · 2008
Δ -0.71-0.87 to -0.55
NCT020581471,170 enrolled · 2014
Δ -0.29-0.38 to -0.19
NCT003184611,091 enrolled · 2006
Δ -1.09-1.30 to -0.88
NCT021289321,089 enrolled · 2014
Δ -0.81-0.96 to -0.67
4 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02964247 phase3completed

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors

Ran2017Enrolled303Registered outcomes26Posted comparisons4ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide, Placebo
Open the trial in the graph
5 · Its place in the literature

Who cites it

26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
    Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Safety and Efficacy of GLP-1 Receptor Agonists and SGLT2 Inhibitors Among Veterans With Type 2 Diabetes.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2022
    Article
  20. Review
6 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

7 · Who and what money

Authors and funding

10 authors at 8 institutions in 8 countries.

Lawrence BlondeOchsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, Louisiana, United States.ORCID 0000-0003-0492-6698
Lidia BelousovaAlmazov National Medical Research Centre, Saint-Petersburg, Russian Federation.
Udi FainbergNovo Nordisk A/S, Søborg, Denmark.
Pedro A Garcia-HernandezEndocrinology Service, University Hospital, Monterrey, Mexico.
Sunil M JainEndocrinology, TOTALL Diabetes Hormone Institute, Indore, Madhya Pradesh, India.
Margit S KaltoftNovo Nordisk A/S, Søborg, Denmark.
Ofri MosenzonDiabetes Unit, Division of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Jalal NafachDubai Diabetes Center, Dubai Health Authority, Dubai, United Arab Emirates.
Mads Sundby PalleNovo Nordisk A/S, Søborg, Denmark.
Rosangela ReaEndocrinology and Metabolism Service (SEMPR), Universidade Federal do Paraná, Curitiba, Brazil.
Novo Nordisk (Denmark) · DKDubai Health Authority · AEFederal Almazov North-West Medical Research Centre · RUHebrew University of Jerusalem · ILOchsner Medical Center · USTOTALL Diabetes Hormone Institute · INUniversidade Federal do Paraná · BRUniversity of Monterrey · MX

Funding

This study was funded by Novo Nordisk A/S.
8 · The paper itself

Abstract

The marked sentences are the ones the graph read a number from.

aimTo compare the effect of liraglutide or placebo added on to sodium-glucose co-transporter-2 inhibitor (SGLT2i) ± metformin on glycaemic control in patients with type 2 diabetes. MATERIALS AND

methodsPatients with type 2 diabetes on a stable SGLT2i dose ± metformin (with HbA1c 7.0%-9.5% and body mass index [BMI] ≥ 20 kg/m

resultsOf 303 patients randomized (one in error), 280 completed treatment. Mean changes in HbA1c from baseline to week 26 with liraglutide (n = 202) and placebo (n = 100) were - 0.98% and - 0.30%, respectively (estimated treatment difference [ETD]: -0.68% [95% CI: -0.89, -0.48]; P < 0.001). Mean body weight changes from baseline were - 2.81 versus -1.99 kg, respectively (ETD: -0.82 kg [95% CI: -1.73, 0.09]; P = 0.077); 51.8% of liraglutide-treated patients achieved HbA1c < 7.0% versus 23.2% receiving placebo (odds ratio: 5.1 [95% CI: 2.67, 9.87]; P < 0.001). More patients treated with liraglutide reported ≥1 treatment-emergent adverse events (66.3%) versus placebo (47.0%).

conclusionsLiraglutide significantly improved glycaemic control compared with placebo in patients with type 2 diabetes, insufficiently controlled with SGLT2is with/without metformin, with no unexpected safety findings.

Indexed as

Diabetes Mellitus, Type 2MetforminSodium-Glucose Transporter 2 InhibitorsSymportersAdultAgedBlood GlucoseDouble-Blind MethodDrug Therapy, CombinationFemaleGlucoseGlycated HemoglobinHumansHypoglycemic AgentsLiraglutideMaleBlood GlucoseGlucoseGlycated HemoglobinHypoglycemic AgentsLiraglutideMetforminSodiumSodium-Glucose Transporter 2 InhibitorsSymportersglucagon-like peptide-1liraglutiderandomized trialsodium-glucose co-transporter-2 inhibitor

Identifiers

PMID31984646
PMCPMC7317838
OpenAlexW3001507139

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.